Please ensure Javascript is enabled for purposes of website accessibility

Why Zomedica Stock Dropped Today

By Joe Tenebruso - Mar 23, 2021 at 6:18PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Investors who bought the rumor now appear to be selling the news.

What happened

Shares of Zomedica (ZOM -0.25%) fell 10.5% Tuesday, furthering the decline in the veterinary health company's stock price over the past week.

So what

Zomedica's shares have shed roughly 28% of their value since the company announced the first sale of its Truforma system on March 16. The diagnostic platform for dogs and cats is Zomedica's first commercial product. Investors have high hopes for its potential to help veterinarians deliver better healthcare to pets -- while fueling Zomedica's revenue and profit growth along the way.

A person is pointing to a stock chart that rises sharply and then falls.

Image source: Getty Images.

Zomedica first announced its plans to commercialize Truforma back on Nov. 13. In the months that followed, traders bid up the company's stock price by a staggering 2,600%. After such a massive move, many investors apparently decided to take profits upon news of Zomedica's first sale.

Now what

Zomedica's recent stock price movements appear to be a classic "buy the rumor, sell the news" event. Traders on Reddit and other social media sites have hyped Zomedica's growth prospects in recent weeks, which has helped to propel the huge surge in its stock price.

Although Truforma could capture a significant share of a pet diagnostics market that's projected to reach $2.8 billion by 2024, Zomedica's stock price may have simply come too far, too fast. The company's announcement of its first sale likely helped remind investors of just how small its current revenue base is, as well as the risks of investing in an early-stage growth company, and they decided to take some of their winnings off the table.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Zomedica Pharmaceuticals Corp. Stock Quote
Zomedica Pharmaceuticals Corp.
$0.24 (-0.25%) $0.00

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/28/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.